Adiponectin Anti-Tumor Agent Inhibits Liver Carcinogenesis
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The relationship between blood adiponectin concentration and illness in obese patients is not sufficiently demonstrated, and there is a need for an effective anti-tumor agent that can inhibit carcinogenesis, particularly in the liver.
Innovation Solution
An anti-tumor agent containing adiponectin as an active ingredient, administered via injection, which inhibits carcinogenesis in various organs including the liver, with dosages ranging from 1 to 100 mg/kg/day, and can be used prophylactically or therapeutically.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If adiponectin is used as an anti-tumor agent, then carcinogenesis inhibition is achieved, but the relationship between blood adiponectin concentration and illness in obese patients remains insufficiently demonstrated
Solution Approach 1:
The patent performs preliminary research and investigation to establish the relationship between blood adiponectin concentration and carcinogenesis risk before clinical application. This preliminary action includes identifying obese patients with low adiponectin levels as high-risk groups and conducting foundational studies to demonstrate the correlation between reduced adiponectin and tumor development, thereby providing the scientific basis for subsequent anti-tumor treatments.
2Object-affected harmful factors
If adiponectin concentration is reduced in blood, then carcinogenesis is promoted, but there is no sufficient demonstration of the relationship between concentration and illness
Solution Approach 1:
The patent implements a feedback mechanism by continuously monitoring blood adiponectin concentrations in obese patients and correlating these levels with illness outcomes and carcinogenesis risk. This feedback approach allows for the establishment of quantitative relationships between adiponectin concentration ranges and disease states, enabling risk stratification and personalized treatment decisions based on measured concentration levels.
Solution Approach 2:
The patent replaces traditional mechanical observation methods with biochemical measurement techniques to accurately quantify blood adiponectin concentrations. By using specific biochemical assays and analytical methods, the patent substitutes subjective or indirect indicators with precise quantitative measurements, thereby reliably demonstrating the relationship between adiponectin concentration and carcinogenesis risk.
3Reliability
If conventional anti-tumor treatments are used, then tumor treatment is attempted, but they do not specifically address the role of adiponectin in carcinogenesis inhibition
Solution Approach 1:
The patent applies local quality by targeting the specific adiponectin pathway and mechanism in anti-tumor treatment rather than using general non-specific chemotherapy or radiation. This involves developing treatments that specifically address adiponectin deficiency or dysfunction, such as adiponectin replacement therapy or agents that enhance adiponectin signaling, thereby providing tailored treatment that addresses the unique mechanistic role of adiponectin in carcinogenesis inhibition.
Data Source
AI summary
The present invention provides a new anti-tumor agent containing adiponectin as an active ingredient, particularly, an anti-tumor agent capable of inhibiting carcinogenesis in the liver, use of adiponectin as an anti-tumor agent, and a prophylactic or therapeutic method against a tumor using adiponectin. The administration form may be either oral administration, e.g., by tablets or parenteral administration, e.g., by injection; in the case of intravenous injection for inhibiting carcinogenesis in the liver, the dosage is 1 to 100 mg/kg/day per adult patient.